We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Agilent (A) Expands Use of Cancer Diagnostics in Europe
Read MoreHide Full Article
Agilent Technologies, Inc. (A - Free Report) has witnessed significant growth in Europe and continues to boost its presence there with expanded use of its diagnostic assay, PD-L1 (programmed death-ligand).
The diagnostic assay, PD-L1 IHC 28-8 pharmDx, helps in assessing the survival benefit for non-squamous, non-small cell lung cancer (NSCLC), squamous cell carcinoma of head and neck and melanoma in Europe. It will now help physicians to also assess the survival benefits of patients suffering from Urothelial Cancer (UC). This makes Europe the first region to launch a PD-L1 CE-IVD test for UC globally.
OPDIVO (nivolumab) is an immunotherapy indicated to treat metastatic UC in adults. This therapy was developed by Bristol-Myers Squibb. Reportedly, OPDIVO (nivolumab) therapy demonstrates higher overall chances of survival than chemotherapy in such patients.
Coming to the price performance, in the last one year, shares of Agilent Technologies underperformed the Zacks categorized Electronic Testing Equipment industry. While the industry gained 50.2%, the stock returned 29%.
Healthcare Sector
Currently, the healthcare sector is witnessing a revolution. Personalized medicine is taking center stage as it can provide improved patient care and better manage costs by administering the most appropriate treatment to individuals. It has been found that not all treatments are suitable for patients suffering from a specific disease as some require more specialized tests.
The advancements in personalized medicines could have far-reaching effects on the entire healthcare system as these medicines considerably improve patient care while reducing medical bills.
Agilent has signed several collaborative agreements with pharma and biotech companies including Pfizer (PFE), AstraZeneca (AZN), Bristol-MyersSquibb, Merck & Co., Amgen and Eli Lilly for the treatment of cancer and other diseases.
Bottom Line
Agilent is an original equipment manufacturer (OEM) of a broad-based portfolio of test and measurement products, serving multiple end markets. We remain positive on Agilent’s broad-based portfolio and increased focus on segments with higher growth potential.
Given increasing health awareness among people all over the world, the emergence of cell-based technologies and personalized medicine further increase opportunities for Agilent.
KLA-Tencor delivered a positive earnings surprise of 11.55%, on average, in the last four quarters.
Applied Materials delivered a positive earnings surprise of 3.35%, on average, in the trailing four quarters.
Advanced Energy Industries, Inc. delivered a positive earnings surprise of 10.46%, on average, in the trailing four quarters.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Agilent (A) Expands Use of Cancer Diagnostics in Europe
Agilent Technologies, Inc. (A - Free Report) has witnessed significant growth in Europe and continues to boost its presence there with expanded use of its diagnostic assay, PD-L1 (programmed death-ligand).
The diagnostic assay, PD-L1 IHC 28-8 pharmDx, helps in assessing the survival benefit for non-squamous, non-small cell lung cancer (NSCLC), squamous cell carcinoma of head and neck and melanoma in Europe. It will now help physicians to also assess the survival benefits of patients suffering from Urothelial Cancer (UC). This makes Europe the first region to launch a PD-L1 CE-IVD test for UC globally.
OPDIVO (nivolumab) is an immunotherapy indicated to treat metastatic UC in adults. This therapy was developed by Bristol-Myers Squibb. Reportedly, OPDIVO (nivolumab) therapy demonstrates higher overall chances of survival than chemotherapy in such patients.
Coming to the price performance, in the last one year, shares of Agilent Technologies underperformed the Zacks categorized Electronic Testing Equipment industry. While the industry gained 50.2%, the stock returned 29%.
Healthcare Sector
Currently, the healthcare sector is witnessing a revolution. Personalized medicine is taking center stage as it can provide improved patient care and better manage costs by administering the most appropriate treatment to individuals. It has been found that not all treatments are suitable for patients suffering from a specific disease as some require more specialized tests.
The advancements in personalized medicines could have far-reaching effects on the entire healthcare system as these medicines considerably improve patient care while reducing medical bills.
Agilent has signed several collaborative agreements with pharma and biotech companies including Pfizer (PFE), AstraZeneca (AZN), Bristol-MyersSquibb, Merck & Co., Amgen and Eli Lilly for the treatment of cancer and other diseases.
Bottom Line
Agilent is an original equipment manufacturer (OEM) of a broad-based portfolio of test and measurement products, serving multiple end markets. We remain positive on Agilent’s broad-based portfolio and increased focus on segments with higher growth potential.
Given increasing health awareness among people all over the world, the emergence of cell-based technologies and personalized medicine further increase opportunities for Agilent.
Agilent Technologies, Inc. Price and Consensus
Agilent Technologies, Inc. Price and Consensus | Agilent Technologies, Inc. Quote
Zacks Rank and Stocks to Consider
Agilent carries a Zacks Rank #2 (Buy). A few other favorably placed stocks in the broader technology sector include KLA-Tencor (KLAC - Free Report) and Applied Materials (AMAT - Free Report) , each sporting a Zacks Rank #1 (Strong Buy), while Advanced Energy Industries, Inc. (AEIS - Free Report) , carrying a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
KLA-Tencor delivered a positive earnings surprise of 11.55%, on average, in the last four quarters.
Applied Materials delivered a positive earnings surprise of 3.35%, on average, in the trailing four quarters.
Advanced Energy Industries, Inc. delivered a positive earnings surprise of 10.46%, on average, in the trailing four quarters.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>